A specific and membrane-permeable inhibitor of the InsP3Kinase activity of ITPKA (inositol-1,4,5-trisphosphate-3-kinase A) with IC50 of 20 uM.

b-AP15(NSC687852) is a specific inhibitor of the deubiquitinating enzymes UCHL5 and Usp14 of the 26S proteasome. It blocks the deubiquitinating activity of the 26S proteasome.

BCI-215 (BCI215) is a potent, tumor cell-selective dual specificity MAPK phosphatase (DUSP-MKP) inhibitor.

A prodrug of Brivanib, which is a dual inhibitor of VEGFR2 and FGFR1 with IC50 of 25 nM and 148 nM respectively.

A potent and highly selective CaMKII inhibitor with IC50 of 63 nM.

A potent SHIP2 inhibitor that enhances in vitro insulin signaling through the Akt pathway more efficiently than AS1949490, and ameliorates abnormal glucose metabolism in diabetic (db/db) mice.

Cephalotaxine is an antiviral as well as antitumor agent.

Get 73 has been investigated for the treatment of Alcohol Dependence.

GW 791343 hydrochloride is a P2X7 allosteric modulator.

NDI-091143 is a novel ATP-citrate lyase inhibitor.

Chelerythrine is a potent, cell permeable inhibitor of protein kinase C (IC50 = 660 nM) that does not inhibit tyrosine protein kinases, cAMP-dependent protein kinase, or calcium/calmodulin-dependent protein kinase.

Chelerythrine is a well-known protein kinase C inhibitor, can inhibit telomerase activity, it also can block the human P2X 7 receptor.

Cinaciguat is an activator of sGC that binds to a regulatory site, resulting in activation in an NO-independent manner (Kd = 3.2 nM).

Cintirorgon (LYC-55716) is novel oral RAR-related orphan receptor γ (RORγ) agonist.

Cisapride is a SR-4 agonist also known as Enteropride

Cl-amidine is a cell-permeable compound that acts as a pan PAD inhibitor (IC50 = 0.8 µM, 6.2 µM and 5.9 µM for PAD1, PAD3, and PAD4, respectively) in enzymatic assays.

CM-346 increased the power of the low-frequency θ-rhythm (4.8–5.8 Hz) and the dominant activity peak (6.0–7.2 Hz) and decreased the spectral power in the 19–20 Hz band.

CNX-774 is a potent, selective, and orally available small molecule inhibitor of Btk (IC50< 1 nM) that forms a ligand-directed covalent bond with Cys-481, a non-conserved amino acid within the active site of the enzyme.

Cosan-528 is a bioactive chemical.

CP-105696 is a potent and selective Leukotriene B4 Receptor antagonist, with an IC50 of 8.42 nM.

CP-640186 Hcl is an isozyme-nonselective acetyl-CoA carboxylase (ACC) inhibitor with IC50s of 53 nM and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2 respectively; with improved metabolic stability vs CP-610431.

GW-870086 is a glucocorticoid receptor agonist potentially for the treatment of asthma and atopic dermatitis.

CP-671305 is a potent and selective inhibitor of phosphodiesterase 4.

T16Ainh-A01 is an inhibitor of the calcium-activated chloride channel TMEM16A, inhibits Ca2+-activated Cl− channel (CACC) activity in TMEM16A-transfected FRT cells with IC50 of 1 uM; T16Ainh-A01 (1-30 uM) inhibited single calcium (Ca2+)-activated chloride (Cl−) channels and whole cell currents activated by 500 nM free Ca2+; T16Ainh-A01 relaxed mouse thoracic aorta pre-contracted with methoxamine with an IC50 of 1.6 uM and suppressed the methoxamine concentration-effect curve; blocks calcium-activated chloride channels in vascular smooth muscle cells and relaxes murine and human blood vessels.

FGTI-2734 is a RAS C-terminal mimetic dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT-1) inhibitor. It can prevent membrane localization of KRAS, hence solving KRAS resistance problem and thwarting mutant KRAS patient-derived pancreatic tumors.

Sacubitrilat, also known as LBQ-657, is endopeptidase inhibitor. Sacubitril is a prodrug that is activated to LBQ657 by de-ethylation via esterases. LBQ657 inhibits the enzyme neprilysin, which is responsible for the degradation of atrial and brain natriuretic peptide, two blood pressure lowering peptides that work mainly by reducing blood volume.

CSF1R-IN-22 is a potent, cellular active and orally bioavailable CSF1R inhibitor with IC50 of 0.5 nM, displays 120-fold selectivity over c-Kit; has improved metabolic stability and Caco2 permeability.

CPI-613 is an E1α pyruvate dehydrogenase (PDH) modulator that prevents cancer cells from metabolizing glucose for energy. CPI-613 has been granted orphan drug status by the US FDA for pancreatic cancer.

CTEP is a novel, long-acting, orally bioavailable allosteric antagonist of mGlu5 receptor with IC50 of 2.2 nM.

Cucurbitacin IIa has anti-cancer, anti-bacterial, and anti-inflammatory effects, it can induce apoptosis and enhance autophagy; it also can disrupt the actin cytoskeleton and direct the cell to undergo PARP-mediated apoptosis through the inhibition of sur